CytomX Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.65
- Today's High:
- $1.73
- Open Price:
- $1.7
- 52W Low:
- $1.17
- 52W High:
- $3.02
- Prev. Close:
- $1.69
- Volume:
- 896082
Company Statistics
- Market Cap.:
- $112.34 million
- Book Value:
- 0.432
- Revenue TTM:
- $71.94 million
- Operating Margin TTM:
- -127.4%
- Gross Profit TTM:
- $69.57 million
- Profit Margin:
- -135.65%
- Return on Assets TTM:
- -19.17%
- Return on Equity TTM:
- -139.27%
Company Profile
CytomX Therapeutics Inc had its IPO on 2015-10-08 under the ticker symbol CTMX.
The company operates in the Healthcare sector and Biotechnology industry. CytomX Therapeutics Inc has a staff strength of 174 employees.
Stock update
Shares of CytomX Therapeutics Inc opened at $1.7 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $1.65 - $1.73, and closed at $1.7.
This is a +0.59% increase from the previous day's closing price.
A total volume of 896,082 shares were traded at the close of the day’s session.
In the last one week, shares of CytomX Therapeutics Inc have slipped by -12.37%.
CytomX Therapeutics Inc's Key Ratios
CytomX Therapeutics Inc has a market cap of $112.34 million, indicating a price to book ratio of 3.8062 and a price to sales ratio of 1.4467.
In the last 12-months CytomX Therapeutics Inc’s revenue was $71.94 million with a gross profit of $69.57 million and an EBITDA of $-89148000. The EBITDA ratio measures CytomX Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CytomX Therapeutics Inc’s operating margin was -127.4% while its return on assets stood at -19.17% with a return of equity of -139.27%.
In Q3, CytomX Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.8%.
CytomX Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -1.8
Its diluted EPS in the last 12-months stands at $-1.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -1.8. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CytomX Therapeutics Inc’s profitability.
CytomX Therapeutics Inc stock is trading at a EV to sales ratio of 0.7429 and a EV to EBITDA ratio of 0.6936. Its price to sales ratio in the trailing 12-months stood at 1.4467.
CytomX Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $226.49 million
- Total Liabilities
- $97.84 million
- Operating Cash Flow
- $-410000.00
- Capital Expenditure
- $410000
- Dividend Payout Ratio
- 0%
CytomX Therapeutics Inc ended 2023 with $226.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $226.49 million while shareholder equity stood at $28.47 million.
CytomX Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $97.84 million in other current liabilities, 1000.00 in common stock, $-605089000.00 in retained earnings and $949000.00 in goodwill. Its cash balance stood at $95.04 million and cash and short-term investments were $194.29 million. The company’s total short-term debt was $3,961,000 while long-term debt stood at $0.
CytomX Therapeutics Inc’s total current assets stands at $200.28 million while long-term investments were $0 and short-term investments were $99.25 million. Its net receivables were $1.71 million compared to accounts payable of $5.18 million and inventory worth $0.
In 2023, CytomX Therapeutics Inc's operating cash flow was $-410000.00 while its capital expenditure stood at $410000.
Comparatively, CytomX Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.7
- 52-Week High
- $3.02
- 52-Week Low
- $1.17
- Analyst Target Price
- $2.82
CytomX Therapeutics Inc stock is currently trading at $1.7 per share. It touched a 52-week high of $3.02 and a 52-week low of $3.02. Analysts tracking the stock have a 12-month average target price of $2.82.
Its 50-day moving average was $2.33 and 200-day moving average was $1.76 The short ratio stood at 1.12 indicating a short percent outstanding of 0%.
Around 134.1% of the company’s stock are held by insiders while 5789.3% are held by institutions.
Frequently Asked Questions About CytomX Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.